Revolutionary treatment for
Pre-term labor & Labor induction
Affects millions of women and newborn!
Bioterm Pharmaceuticals Ltd. is the developer of novel therapeutics for the treatment and prevention of pre-term labor and for the induction of labor that cause severe morbidity of millions of newborn worldwide.
The Company has patented the use of two molecules, its Preventerm molecule for the prevention of pre-term labor (PCT, pending) and its Inducterm molecule (approved patent) for labor induction.
Both molecules have been approved for therapy for unrelated indications, allowing BT a substantial acceleration of regulatory approvals.
BT is currently seeking an equity investment to broaden management, and to enhance marketing and business development activities in the U.S. and Europe.
-Risk Reduction -Fewer Complications -Efficacy -Cost Reduction
Bioterm may become extremely valuable to various players in the healthcare market - especially to leading pharmaceutical companies, healthcare insurers and service providers, and of course, to mothers and babies: